Stock Traders Buy High Volume of Call Options on GRAIL (NASDAQ:GRAL)

GRAIL, Inc. (NASDAQ:GRAL) was the recipient of some unusual options trading on Monday. Stock investors bought 5,910 call options on the company. This represents an increase of approximately 229% compared to the typical daily volume of 1,799 call options.

Key Headlines Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Management will present at the TD Cowen 46th Annual Health Care Conference on Mar. 3 — a chance to update investors on commercial progress and cash‑burn outlook, which can provide clarity and a catalyst for the stock. GRAIL to Present at the TD Cowen 46th Annual Health Care Conference
• Positive Sentiment: Unusually large call‑option activity — investors bought ~5,910 calls (a ~229% jump vs. average) — indicates short‑term bullish positioning and speculative interest that can amplify upside on positive news or guidance. (No link available)
• Positive Sentiment: Analysts set a new target price near $107.83, well above current levels, implying consensus upside from some street analysts and providing a potential support for recovery if fundamentals/clinical news improve. Analysts Set GRAIL, Inc. Target Price at $107.83
• Negative Sentiment: Multiple law‑firm investigations announced (Robbins Geller; Levi & Korsinsky; Kaplan Fox) into potential securities‑law violations — these investigations raise legal, disclosure and reputational risk that can pressure the stock and increase uncertainty for investors. Robbins Geller investigation notice
• Negative Sentiment: Levi & Korsinsky has commenced a probe tied to prior cash‑burn guidance comments, signaling investor scrutiny around past disclosures and financial guidance. Such class‑action/derivative risks can be material. Lost Money on GRAIL, Inc.? Possible Fraud – Contact Levi & Korsinsky Today
• Negative Sentiment: Valuation re‑assessment after an NHS/Galleri trial setback and attendant analyst downgrades/commentary — raises near‑term revenue and adoption uncertainty for GRAIL’s screening product and likely weighs on longer‑term multiples until more favorable trial or commercialization data appear. GRAIL Valuation Reassessed After NHS Galleri Trial Setback
• Negative Sentiment: Sell‑side and independent commentary (e.g., Seeking Alpha piece advising to wait for lower levels) reflects bearish sentiment from some investors and could feed further short‑term selling pressure. GRAIL: The NHS-Galleri Setback – I Would Wait For Low $30s To Buy

Wall Street Analysts Forecast Growth

GRAL has been the subject of a number of recent research reports. Guggenheim raised their price target on shares of GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Robert W. Baird set a $82.00 target price on shares of GRAIL in a report on Friday. TD Cowen began coverage on shares of GRAIL in a research report on Thursday, February 19th. They set a “hold” rating and a $114.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research report on Thursday, January 22nd. Finally, Canaccord Genuity Group reduced their price objective on GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a research note on Friday. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $90.17.

Institutional Trading of GRAIL

A number of institutional investors and hedge funds have recently made changes to their positions in GRAL. N.E.W. Advisory Services LLC purchased a new position in shares of GRAIL during the 4th quarter valued at approximately $26,000. Comerica Bank increased its holdings in GRAIL by 59.2% in the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after acquiring an additional 173 shares in the last quarter. Elyxium Wealth LLC acquired a new position in GRAIL during the fourth quarter worth $31,000. Intesa Sanpaolo S.p.A. purchased a new position in GRAIL during the fourth quarter valued at $44,000. Finally, Ankerstar Wealth LLC acquired a new stake in shares of GRAIL in the fourth quarter valued at about $45,000.

GRAIL Stock Performance

GRAL stock opened at $50.35 on Wednesday. GRAIL has a one year low of $20.44 and a one year high of $118.84. The firm’s fifty day moving average is $94.92 and its 200 day moving average is $76.73. The firm has a market cap of $1.96 billion, a PE ratio of -4.50 and a beta of 4.52.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($2.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.33) by $0.89. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.58%. The business had revenue of $43.60 million during the quarter, compared to the consensus estimate of $43.33 million. Research analysts predict that GRAIL will post -15.15 earnings per share for the current fiscal year.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.